EDITOR’S CHOICE – Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation

Journal: Recent Patents on Anti-Cancer Drug Discovery

Author(s): Juan F. Santibanez*, Suncica Bjelica

Abstract:

Background: IL-17A is a founding member of the IL-17 family that has been implicated in the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. In cancer, IL-17A participates in many key events for tumor development, in part by affecting innate and adaptive immune system and also by direct modulation of many pro-tumor events. Moreover, IL-17A dysregulation at the site of inflammation is associated with rheumatoid arthritis, multiple sclerosis, psoriasis, among others. IL-17A has emerged as a topic of interest and is under profound investigation for its involvement in several types of inflammatory-associated diseases.

Objective: This review aims to present an overview of the state of the art of IL-17A role in cancer and inflammation, as well as to describe recent patents targeting IL-17A with relevant clinical and biological properties for the prevention and treatment of cancer and inflammatory diseases.

Methods: Relevant information was obtained by searching in PubMed using IL-17A or IL-17, cancer and inflammation as keywords, while relevant patents were obtained mainly from Google Patents.

Results: Literature data indicated IL-17A as important biomolecule in the physiopathology of cancer and inflammatory diseases. Whereas, novel patents (2010 to 2017) targeting IL-17A are focused mainly on describing strategies to modulate IL-17A per se, co-modulation by bispecific antibodies to blocking IL-17A and important cytokines for IL-17A functions, upstream mechanisms and compounds to regulate IL-17A expression.

Conclusion: The promising effects of patented agents against IL-17A may open new opportunities to therapeutic intervention targeting at different levels of involvement in the pathogenesis of cancer and inflammatory diseases.

Read more here: http://www.eurekaselect.com/159948/article

 

Press Release for EurekAlert! Probiotics: Novel biosynthetic tool to develop metallic nanoparticles

This research article by Dr. Nida Akhtar et al has been published in Recent Patents on Drug Delivery & Formulation, Volume 11, Issue 1, 2017

 

Probiotics, being live microbes, exert numerous beneficial health effects on the host cells. Such probiotics are commercially available as dietary supplements, foods, pharmaceutical formulations. Yakult, Activia yogurt, DanActive fermented milk provide health benefits like boosting up the immune system, treating digestive problems, mental illness, neurological disorders, cancer, etc. However, the use of probiotic bacteria to develop metallic nanoparticles (MNPs) constitutes novel research nowadays. Research inputs and patent reports according to an article published in the journal Recent Patents on Drug Delivery and Formulation highlight their potential in the field of cosmetics, pharmaceuticals, medicine and biotechnology as well.

Prof. Kamla Pathak, the corresponding author said: “Our review findings reinstate the potential of probiotic bacteria to produce MNPs. Patents (US, EP and WIPO patents) during 2009-2016 reaffirm the research and inspire the scientific community worldwide for future exploration. This is the first review article in this aspect that systematically tracks the intellectual aspects of applications and synthesis of MNPs by probiotic bacteria. Prof. Pathak said, “Our study details the interventions on which research on MNPs is on. Gold, silver, magnetic, selenium, iron oxide, magnetic-optical iron oxide-gold core-shell, magnesium oxide, copper oxide, aluminum oxide, titanium dioxide, zinc oxide nanoparticles have applications ranging from their usage in analytical methodologies to treat and diagnose diseases. Specifically, gold NPs are suggested for drug delivery and treating lymphocytic leukemia; silver and copper NPs for antimicrobial activity and zinc oxide NPs as anti-corrosive, antifungal and as an additive in food products such as breakfast cereals. These NPs need to be explored more as no patent till date was found on them based on their biosynthesis, according to the author’s report.

For more information about the article, please visit: http://www.eurekaselect.com/node/150848/article/probiotics-as-a-tool-to-biosynthesize-metallic-nanoparticles-research-reports-and-patents-survey

Testimonial by Dr. Orfeas Liangos!

05-MAY-V07-SALE

Contributed Article: Update on AKI Biomarker Patents

Wishing A Very Happy Birthday To Dr. Togay Ozbakkaloglu

Print

As the Editor-in-Chief of Recent Patents on Engineering we appreciate your contributions to Bentham Science. For latest articles in the journal, please visit: http://benthamscience.com/journals/recent-patents-on-engineering/

UPCOMING THEMATIC ISSUE

Thematic Issue Proposal Approved For May 2015 on “METABOLIC TARGETING OF CANCERS”

A thematic issue proposal entitled “Metabolic targeting of cancers” has been approved for proposal Recent Patents on Anti-Cancer Drug Discovery. The issue will be published in 2015 issue.

For details on this journal, click: http://benthamscience.com/journal/index.php?journalID=rpacdd

UPCOMING PATENT EBOOK SERIES

Volume 3, 2014 of the Patent e-Book Series “Topics in Anti-Cancer-Research” has been lined up and will be available online soon.

Browse Bentham Science Patent Journals:

Click the link and access the list of patent journals on various topics and fields: http://benthamscience.com/journal/browse-patent-journals.php?pcount=1

BSP Patent Journal- Recent Patents on Biomarkers

Recent Patents on Biomarkers

7-24-2014 11-31-47 AM

ISSN: 2210-3104 (Online)
ISSN: 2210-3090 (Print)

Volume 4, 3 Issues, 2014

Aims & Scope

Recent Patents on Biomarkers publishes review and research articles, and guest edited thematic issues on important recent patents on biomarkers. The coverage includes novel biomarkers in basic, medical, environmental, and pharmaceutical research. A selection of important and recent patents on biomarkers is also included in the journal. The journal is essential reading for all researchers involved in biomarker research and discovery. The journal also covers recent research (where patents have been registered) in fast emerging patent biomarker applications; discovery and validation are covered for drug discovery, clinical development and molecular diagnostics.

Abstracted & Indexed in:

Chemical Abstracts, MediaFinder®-Standard Periodical Directory, J-Gate, PubsHub, CABI.

For more details, visit: http://benthamscience.com/journal/index.php?journalID=rpbm

%d bloggers like this: